Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Salugina S.O.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Gorodetsky V.R.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Fedorov E.S.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Lopatina N.E.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Evsikova М.D.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab

Authors:

Salugina S.O., Gorodetsky V.R., Fedorov E.S., Lopatina N.E., Evsikova М.D.

More about the authors

Journal: Therapeutic Archive. 2017;89(11): 111‑115

DOI: 10.17116/terarkh20178911111-115

Views: 2239

Downloaded: 693

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Salugina SO, Gorodetsky VR, Fedorov ES, Lopatina NE, Evsikova МD. Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab. Therapeutic Archive. 2017;89(11):111‑115. (In Russ.)
https://doi.org/10.17116/terarkh20178911111-115

Close metadata

Recommended articles:

Human diseases treatment via enema fecal microbiota transplantation. Methodological recommendations. Russian Journal of Preventive Medicine. 2024;(6):79-87

Cognitive behavioral therapy in the treatment of patients with chronic migraine and concomitant chronic insomnia: a prospective, randomized trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):110-117

Late-onset schizophrenia and schizophrenia-like psychosis with very late onset. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):32-40

Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy. P.A. Herzen Journal of Oncology. 2024;(5):76-81

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

The paper reviews the publications dealing with Schnitzler syndrome, a rare autoinflammatory disease, and describes the authors’ own clinical observation. It describes the first Russian experience in successfully using the interleukin-1 inhibitor canakinumab to treat this disease.

Keywords:

autoinflammatory diseases

Schnitzler syndrome

therapy

IL-1 inhibitors

canakinumab

Authors:

Salugina S.O.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Gorodetsky V.R.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Fedorov E.S.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia ,

Lopatina N.E.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Evsikova М.D.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

List of references:

Simon A, Asli B, Braun-Falco M et al. Schnitzler Syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562-568.
Lipsker D, Veran Y, Grunenberger F et al. The Schnitzler Syndrome Four new cases and review of the literature. Medicine. 2001;80:37-44.
De Koning HD., Bodar EJ., van der Meer JW. Schnitzler Syndrome Study Group. Schnitzler Syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37:137-148.
Schnitzler L, Schubert B,Boasson M et al. Urticaire chronique, lesions osseuses, macroglobulinemie IgM maladie de Waldenstrom. Bull Soc Franc Derm Syph. 1974;81:363.
Lipsker D. The Schnitzler syndrome Orphanet Journal of Rare Diseases. 2010;5:38-45.
Saurat JH, Schifferly J, Steiger G et al. Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution and receptor-binding inhibition-higher frequency in Schnitzler’s syndrome (urticaria and macroglobulinemia). J Allergy Clin Immunol. 1991;88:244-56.
Sokumbi O, Drage LA, Peters MS. Clinical and histopathologic review of Schnitzler syndrome: the Mayo Clinic experience (1972-2011). J Am Acad Dermatol. 2012;67:1289-1295.
Tinazzi E, Puccetti A, Patuzzo G et al. Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: report of two new cases and review of the literature. Autoimmun Rev. 2011;10:404-409.
Neel A, Henry B, Barbarot S et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler syndrome: a french multicenter study Autoimmunity. Reviews. 2014;13:1035-1041.
Eiling E, Moller M, Kreiselmaier I et al. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol. 2007;57:361-364.
Zuberbier T, Maurer M. Urticarial Vasculitis and Schnitzler Syndrome. Immunol Allergy Clin N Am. 2014; 34:141-147.
De Castro FR, Masouye I, Winkelmann RK, Saurat JH. Urticarial pathology in Schnitzler’s (hyper-IgM) syndrome. Dermatology. 1996;193:94-99.
Gattorno M. Kriopirin - assotsiirovannyi periodicheskii sindrom (reprint). Voprosy sovremennoi pediatrii. 2013;12 (1):57-62. https://doi.org/10.15690/vsp.v14i3.1372
Caso F, Rigante D, Vitale A et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. International Journal of Rheumatology. 2013;Article ID513782,15pages. https://doi.org/10.1155/2013/513782
Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clinical entity. Haematol. 2013;98(10): 1581-1585.
Claes K, Bammens B, Delforge M et al. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol. 2008;158:182-184.
Dalle S, Balme B, Sebban C et al. Schnitzler syndrome associated with systemic marginal zone B-cell lymphoma. Br J Dermatol. 2006;155:827-829.
Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum. 2005;52:2226-2227.
Gran JT, Midtvedt Q,Haug S, Aukrust P. Treatment of Schnitzler syndrome with anakinra: report of three cases and review of the literature. Scand J Rheumatol. 2011;40:74-79.
Asli B, Bievenu B, Cardoliani F et al. Chronic Urticaria and Monoclonal IgM gammopathy (Schnitzler syndrome). Report of 11 cases treated with Pefloxacin. Arch Dermatol. 2007;143:1046-1050.
Billey T, Beldjerd M, Popa L, Lassoued S. Schnitzler syndrome: a dramatic improvement with anakinra. Presse Med. 2010;39: 1338-1339.
Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129:848-850.
Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome:an open-label study. Allergy. 2012;67:943-950.
De Koning HD, Schalkwijk J, van der Meer JW, Simon A. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol. 2011;128: 1352-1354.
Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum. 2013;42:413-416.
Krause K, Tsianakas A,Wagner N et al. Efficacy and safety of canakinubab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. 2016; J Allergy Clin Immunol. 2016 Sep 19. pii: S0091-6749(16)30968-X. https://doi.org/10.1016/j.jaci.2016.07.041
Federici S, Martini A, Gattorno M. The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Frontiers un Immunology. 2013;4:351.
Masters SL, Simon A, Aksetijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol. 2009;27:621-668.
Eiling E, Schroder JO, Gross WL et al. The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy — an autoinflammatory syndrome? J Dtsch Dermatol Ges. 2008;6:626-631.

Close metadata

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.